BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2025 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
BTAI on Nasdaq
Shares outstanding
19,770,250
Price per share
$1.53
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
2,342,780
Total reported value
$5,992,669
% of total 13F portfolios
0%
Share change
+1,724,704
Value change
+$4,499,763
Number of holders
35
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
INTEGRATED CORE STRATEGIES (US) LLC 5.2% $3,485,100 1,028,053 Millennium Management LLC 29 Sep 2025
ARMISTICE CAPITAL, LLC 5% -50% $564,737 -$9,229,922 288,131 -94% Armistice Capital, LLC 31 Mar 2025

As of 30 Sep 2025, 35 institutional investors reported holding 2,342,780 shares of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI). This represents 12% of the company’s total 19,770,250 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) together control 12% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MILLENNIUM MANAGEMENT LLC 5.2% 1,028,053 0% $2,631,816
OAKTREE CAPITAL MANAGEMENT LP 1.2% 241,188 0% 0.01% $617,443
FMR LLC 1% 198,600 0% $508,416
VANGUARD GROUP INC 0.97% 192,125 +921% 0% $491,840
GEODE CAPITAL MANAGEMENT, LLC 0.63% 125,240 +344% 0% $320,622
XTX Topco Ltd 0.57% 113,364 +384% 0.02% $290,212
BlackRock, Inc. 0.43% 84,282 +374% 0% $215,762
STATE STREET CORP 0.27% 52,718 0% $134,958
UBS Group AG 0.22% 43,542 +9.2% 0% $111,468
Oaktree Fund Advisors, LLC 0.22% 42,913 0% 0.2% $109,857
NORTHERN TRUST CORP 0.19% 37,733 0% $96,597
JONES FINANCIAL COMPANIES LLLP 0.18% 36,000 +38% 0% $97,200
HighTower Advisors, LLC 0.18% 35,000 +42% 0% $89,600
Foundations Investment Advisors, LLC 0.15% 29,549 0% $75,645
SLT Holdings LLC 0.15% 29,500 0.05% $75,520
WELLS FARGO & COMPANY/MN 0.08% 16,316 -3.6% 0% $41,769
DIVERSIFY WEALTH MANAGEMENT, LLC 0.08% 15,000 0% 0% $28,500
BANK OF AMERICA CORP /DE/ 0.03% 6,881 +345% 0% $17,615
IFP Advisors, Inc 0.02% 4,370 0% $11,187
Tower Research Capital LLC (TRC) 0.02% 3,933 +187% 0% $10,068
GROUP ONE TRADING LLC 0.01% 2,249 +77% 0% $5,757
MORGAN STANLEY 0.01% 1,641 +3.9% 0% $4,201
NewEdge Advisors, LLC 0.01% 1,331 +4194% 0% $3,408
CITIGROUP INC 0% 355 0% $909
AllSquare Wealth Management LLC 0% 175 0% 0% $448

Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 2,342,780 $5,992,669 +$4,499,763 $2.56 35
2025 Q2 603,081 $1,090,541 +$395,829 $1.81 33
2025 Q1 378,983 $769,811 +$769,716 $2.03 31